NCT04994288View on ClinicalTrials.gov

A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

547

Participants

Timeline

Start Date

August 3, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

August 16, 2023

Conditions
Type2 Diabetes
Interventions
BIOLOGICAL

Supaglutide injection

Supaglutide 1mg/0.5ml , 2mg/0.5ml ,3mg /0.5ml

OTHER

placebo injection

placebo injection 0.5ml

Trial Locations (1)

210008

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.

OTHER

NCT04994288 - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients(SUPER-1) | Biotech Hunter | Biotech Hunter